Evidence map›Paper›PMID 35990965›Full record

ArticleFrontiers in cardiovascular medicine2022

Treatment patterns and use of healthcare resources of patients with atherosclerotic cardiovascular disease and hypercholesterolemia and patients with familial hypercholesterolemia in Spain: Protocol of the Reality study.

Vivencio Barrios, Mar Castellanos, Raquel Campuzano Ruiz, Jorge Francisco Gómez Cerezo, Isabel Egocheaga Cabello, José M Gámez, Icíar Martínez López, José María Mostaza, Nuria Morant Talamante, Javier Parrondo and 4 more

Abstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Vivencio BarriosCardiology Service, University Hospital Ramón y Cajal, Madrid, Spain.
Mar CastellanosNeurology Service, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain.
Raquel Campuzano RuizCardiac Rehabilitation, Cardiology Service, Hospital Universitario Alcorcón, Madrid, Spain.
Jorge Francisco Gómez CerezoInternal Medicine Service, Hospital Universitario Infanta Sofía, Madrid, Spain.
Isabel Egocheaga CabelloFamily Medicine Service, Centro de Salud Isla de Oza, Madrid, Spain.
José M GámezCardiology Service, Hospital Universitario Son Llátzer, Palma, Spain.
Icíar Martínez LópezPharmacy Service and Molecular Diagnostics and Clinical Genetics Unit, Hospital Universitario Son Espases, Palma, Spain.
José María MostazaInternal Medicine Section, Hospital Universitario La Paz, Madrid, Spain.
Nuria Morant TalamanteMedical Department, Novartis Pharmaceuticals, Barcelona, Spain.
Javier ParrondoHealth Economics Department, Novartis Pharmaceuticals, Barcelona, Spain.
Aram Sicras NavarroHealth Economics and Outcomes Research Department, Atrys Health, Barcelona, Spain.
Inés Pérez RománHealth Economics and Outcomes Research Department, Atrys Health, Madrid, Spain.
Antoni Sicras-MainarHealth Economics and Outcomes Research Department, Atrys Health, Barcelona, Spain.
Vicente Pallarés-CarrataláUnidad de Vigilancia de la Salud, Unión de Mutuas, Castellón, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Atherosclerotic cardiovascular diseases (ASCVD) and dyslipidemia are associated to a higher risk of cardiovascular events, mortality, use of healthcare resources and costs. In Spain, the evidence about the administration of lipid-lowering treatments in clinical practice, and their clinical effectiveness in patients with ASCVD and hypercholesterolemia and patients with FH is scarce. Therefore, a multidisciplinary working group of cardiologists, family physicians, internal medicine specialists and neurologists was gathered for the Reality study. The aim of this study is to describe the demographic and clinical characteristics, comorbidities, and concomitant medication of patients with ASCVD and hypercholesterolemia and of patients with familial hypercholesterolemia (FH). The use of healthcare resources and costs associated to the management of these diseases after their diagnosis were also considered. Methods: This is an observational and retrospective study, based on the BIG-PAC Discussion: This study aims to analyze the treatment patterns and use of healthcare resources of ASCVD and FH in Spain. The prevalence of these disorders will also be estimated. Due to the high morbidity and mortality associated with these diseases, it is expected that our study will provide useful information for healthcare systems and decision makers to improve the management of these disabling diseases.

Indexed as

atherosclerosishealth care costshealth resourceshypercholesterolemiahypolipidemic agents

Identifiers

PMID35990965
PMCPMC9386132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.